Combination of HER2-Targeted Antibodies (Trastuzumab plus Pertuzumab) is Effective Against HER2 Amplified Ovarian Cancer Xenograft Models

被引：0
|
作者：
Langdon, S. P. [1 ]
Sims, A. H. [1 ]
Harrison, D. J. [2 ]
机构：
[1] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[2] Univ St Andrews, St Andrews, Fife, Scotland
来源：
JOURNAL OF PATHOLOGY | 2013年 / 231卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [1] Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
    Veeraraghavan, Jamunarani
    Gutierrez, Carolina
    Sethunath, Vidyalakshmi
    Mehravaran, Sepideh
    Giuliano, Mario
    Shea, Martin J.
    Mitchell, Tamika
    Wang, Tao
    Nanda, Sarmistha
    Pereira, Resel
    Davis, Robert
    Goutsouliak, Kristina
    Qin, Lanfang
    De Angelis, Carmine
    Diala, Irmina
    Lalani, Alshad S.
    Nagi, Chandandeep
    Hilsenbeck, Susan G.
    Rimawi, Mothaffar F.
    Osborne, C. Kent
    Schiff, Rachel
    NPJ BREAST CANCER, 2021, 7 (01)
  • [2] Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
    Jamunarani Veeraraghavan
    Carolina Gutierrez
    Vidyalakshmi Sethunath
    Sepideh Mehravaran
    Mario Giuliano
    Martin J. Shea
    Tamika Mitchell
    Tao Wang
    Sarmistha Nanda
    Resel Pereira
    Robert Davis
    Kristina Goutsouliak
    Lanfang Qin
    Carmine De Angelis
    Irmina Diala
    Alshad S. Lalani
    Chandandeep Nagi
    Susan G. Hilsenbeck
    Mothaffar F. Rimawi
    C. Kent Osborne
    Rachel Schiff
    npj Breast Cancer, 7
  • [3] Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
    Juin Park
    Sun Kyoung Kang
    Woo Sun Kwon
    Inhye Jeong
    Tae Soo Kim
    Seo Young Yu
    Sang Woo Cho
    Hyun Cheol Chung
    Sun Young Rha
    Scientific Reports, 13
  • [4] Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
    Park, Juin
    Kang, Sun Kyoung
    Kwon, Woo Sun
    Jeong, Inhye
    Kim, Tae Soo
    Yu, Seo Young
    Cho, Sang Woo
    Chung, Hyun Cheol
    Rha, Sun Young
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [5] The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
    Nami, Babak
    Maadi, Hamid
    Wang, Zhixiang
    CANCERS, 2019, 11 (03)
  • [6] Truncated HER2: implications for HER2-targeted therapeutics
    Zagozdzon, Radoslaw
    Gallagher, William M.
    Crown, John
    DRUG DISCOVERY TODAY, 2011, 16 (17-18) : 810 - 816
  • [7] Loss of HER2 after HER2-targeted treatment
    Ignatov, Tanja
    Gorbunow, Franceska
    Eggemann, Holm
    Ortmann, Olaf
    Ignatov, Atanas
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (02) : 401 - 408
  • [8] Loss of HER2 after HER2-targeted treatment
    Tanja Ignatov
    Franceska Gorbunow
    Holm Eggemann
    Olaf Ortmann
    Atanas Ignatov
    Breast Cancer Research and Treatment, 2019, 175 : 401 - 408
  • [9] Patient-derived xenograft (PDX) models with differential HER2 expression for preclinical evaluation of HER2-targeted therapies
    Yang, Xiaoliu
    Guo, Shiying
    Wang, Huiyi
    Su, Xu
    Zhao, Jing
    Gao, Xiang
    Ju, Cunxiang
    CANCER RESEARCH, 2024, 84 (06)
  • [10] Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer
    Fakih, Marwan G.
    ONCOLOGIST, 2018, 23 (04): : 474 - 477
12345